Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2022 08:00 ET | Source: Alector, Inc.

Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial

Treatment with AL001 (latozinemab) demonstrated target engagement and resulted in increases in progranulin levels in all patients FTD-C9orf72 patients treated with latozinemab demonstrated a trend...
March 09, 2022 07:00 ET | Source: Alector, Inc.

Alector to Present at Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...
March 08, 2022 07:00 ET | Source: Alector, Inc.

Alector to Present New AL001 Data at AD/PD™ 2022

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced an oral presentation...
March 01, 2022 16:30 ET | Source: Alector, Inc.

Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the...
March 01, 2022 16:05 ET | Source: Alector, Inc.

Alector to Participate at the Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology...
February 24, 2022 16:05 ET | Source: Alector, Inc.

Alector Reports Fourth Quarter and Full Year 2021 Financial Results

CTAD and SITC presentations in fourth quarter highlight progress across immuno-neurology and immuno-oncology portfolio Over $900 million in pro forma cash, cash equivalents and investments supports...
February 07, 2022 08:30 ET | Source: Alector, Inc.

Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology...
January 03, 2022 16:30 ET | Source: Alector, Inc.

Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation...
December 15, 2021 08:30 ET | Source: Alector, Inc.

Alector Announces Appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of...
November 12, 2021 13:50 ET | Source: Alector, Inc.

Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of INFRONT-2 Phase 2 Open-label Clinical Study

Progranulin Levels Increase to Normal Ranges Multiple Biomarkers of Disease Showed Improvement from Baseline with AL001 Treatment, Including GFAP, a Prognostic Marker for FTD Associated with Brain...